Pfizer, Ranbaxy Sued Over Delay Of Generic Lipitor

Law360 (May 22, 2020, 6:25 PM EDT) -- Pfizer Inc. and Ranbaxy Inc. were hit Friday with a proposed class action alleging drug wholesalers overpaid billions of dollars for the high-cholesterol medicine Lipitor because of a purported pay-for-delay scheme to stifle generic competition.

The complaint by Puerto Rico-based health care products distributor César Castillo LLC targets a "reverse payment" arrangement in which Pfizer paid Ranbaxy to hold off on rolling out its generic version of Lipitor even beyond the expiration of Pfizer's patent, forcing direct purchasers to pay for brand-name atorvastatin calcium longer than necessary.

The conduct violated federal antitrust laws against monopolies and restraint of trade, according to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!